20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Back to Search
Print
Bookmark Trial

NCT04382326

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Priti Desai, M.D. Inc.
Covina, California, 91723, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
42-98 days
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.

- Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis)


- Major known congenital malformation or serious chronic disorder


- Other acute or chronic medical or psychiatric condition or laboratory abnormality that
may increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results


- Previous receipt of >1 dose of hepatitis B vaccine; or receipt of a single hepatitis B
vaccine dose administered at >30 days old, or previous receipt of any licensed or
investigational pneumococcal vaccine, or planned receipt through study participation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Espoo,
  2. Järvenpää,
  3. Oulu,
  4. Pori,
  5. Seinajoki,
  6. Turku,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Fukuoka-City, Fukuoka
  2. Akashi-City, Hyōgo
  3. Kumamoto-shi, Kumamoto
  4. Setagaya-ku, Tokyo
  5. Shinjuku-ku, Tokyo
  6. Suginami-ku, Tokyo
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Mobile, Alabama
  2. Chandler, Arizona
  3. Phoenix, Arizona
  4. San Diego, California
  5. Coral Gables, Florida
  6. Crystal River, Florida
  7. Hialeah, Florida
  8. Miami, Florida
  9. El Dorado, Kansas
  10. Wichita, Kansas
  11. Wichita, Kansas
  12. New Orleans, Louisiana
  13. Elkridge, Maryland
  14. Rockville, Maryland
  15. Omaha, Nebraska
  16. Las Vegas, Nevada
  17. Las Vegas, Nevada
  18. Charlotte, North Carolina
  19. Greensboro, North Carolina
  20. Hickory, North Carolina
  21. Raleigh, North Carolina
  22. Raleigh, North Carolina
  23. Wilmington, North Carolina
  24. Fargo, North Dakota
  25. Cincinnati, Ohio
  26. Cincinnati, Ohio
  27. Cleveland, Ohio
  28. Franklin, Ohio
  29. Warwick, Rhode Island
  30. Little River, South Carolina
  31. Mount Pleasant, South Carolina
  32. Bristol, Tennessee
  33. Nashville, Tennessee
  34. Austin, Texas
  35. Fort Worth, Texas
  36. Fort Worth, Texas
  37. Houston, Texas
  38. McKinney, Texas
  39. Pearland, Texas
  40. San Antonio, Texas
  41. Tomball, Texas
  42. Tomball, Texas
  43. Draper, Utah
  44. Salt Lake City, Utah
  45. Salt Lake City, Utah
  46. South Jordan, Utah
  47. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
  1. Covina, California
  2. West Covina, California
  3. Lake Mary, Florida
  4. Loxahatchee Groves, Florida
  5. Baltimore, Maryland
  6. Frederick, Maryland
  7. East Setauket, New York
  8. East Setauket, New York
  9. Stony Brook, New York
  10. Stony Brook, New York
  11. Houston, Texas
  12. Cullman, Alabama
  13. Dothan, Alabama
  14. Phoenix, Arizona
  15. Fayetteville, Arkansas
  16. Bell Gardens, California
  17. Bellflower, California
  18. Gardena, California
  19. Hawthorne, California
  20. Los Angeles, California
  21. Ontario, California
  22. Paramount, California
  23. Valencia, California
  24. Colorado Springs, Colorado
  25. Apopka, Florida
  26. Boynton Beach, Florida
  27. Gainesville, Florida
  28. Gainesville, Florida
  29. Hialeah, Florida
  30. Homestead, Florida
  31. Miami Lakes, Florida
  32. Miami, Florida
  33. Miami, Florida
  34. Tampa, Florida
  35. Chamblee, Georgia
  36. Columbus, Georgia
  37. Columbus, Georgia
  38. Ammon, Idaho
  39. Idaho Falls, Idaho
  40. Idaho Falls, Idaho
  41. Idaho Falls, Idaho
  42. Idaho Falls, Idaho
  43. Idaho Falls, Idaho
  44. Nampa, Idaho
  45. Ankeny, Iowa
  46. Des Moines, Iowa
  47. Des Moines, Iowa
  48. West Des Moines, Iowa
  49. El Dorado, Kansas
  50. Bardstown, Kentucky
  51. Louisville, Kentucky
  52. Baton Rouge, Louisiana
  53. Covington, Louisiana
  54. Haughton, Louisiana
  55. Metairie, Louisiana
  56. Gulfport, Mississippi
  57. Missoula, Montana
  58. Lincoln, Nebraska
  59. Lincoln, Nebraska
  60. Albuquerque, New Mexico
  61. East Syracuse, New York
  62. Liverpool, New York
  63. Dayton, Ohio
  64. Dayton, Ohio
  65. Fairfield, Ohio
  66. South Euclid, Ohio
  67. East Norriton, Pennsylvania
  68. Erie, Pennsylvania
  69. Fort Washington, Pennsylvania
  70. Charleston, South Carolina
  71. Cheraw, South Carolina
  72. North Charleston, South Carolina
  73. Bristol, Tennessee
  74. Clarksville, Tennessee
  75. Kingsport, Tennessee
  76. Corpus Christi, Texas
  77. Houston, Texas
  78. Longview, Texas
  79. McAllen, Texas
  80. San Antonio, Texas
  81. Kaysville, Utah
  82. Layton, Utah
  83. Murray, Utah
  84. Roy, Utah
  85. Saint George, Utah
  86. Syracuse, Utah
  87. Charlottesville, Virginia
  88. Charlottesville, Virginia
  89. Vancouver, Washington
  90. Guayama,
  91. Trujillo Alto,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Official Title  ICMJE A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
Brief Summary 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Pneumococcal Disease
Intervention  ICMJE
  • Biological: 20-valent pneumococcal conjugate vaccine
    20-valent pneumococcal conjugate vaccine
  • Biological: 13-valent pneumococcal conjugate vaccine
    13-valent pneumococcal conjugate vaccine
Study Arms  ICMJE
  • Experimental: 20-valent pneumococcal conjugate vaccine
    Pneumococcal conjugate vaccine
    Intervention: Biological: 20-valent pneumococcal conjugate vaccine
  • Active Comparator: 13-valent pneumococcal conjugate vaccine
    Pneumococcal conjugate vaccine
    Intervention: Biological: 13-valent pneumococcal conjugate vaccine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 7, 2020)		2000
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 7, 2022
Estimated Primary Completion Date May 7, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Major known congenital malformation or serious chronic disorder
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results
  • Previous receipt of >1 dose of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old, or previous receipt of any licensed or investigational pneumococcal vaccine, or planned receipt through study participation
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 42 Days to 98 Days   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04382326
Other Study ID Numbers  ICMJE B7471011
2019-003305-10 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP